STCube

STCube Debt/EBITDA

The Total Debt to EBITDA Ratio of STCube (052020.KQ) as of Oct 24, 2026 is -0.47. In the previous year, Total Debt to EBITDA Ratio was -0.07 — a change of 570.40% (lower).

Debt/EBITDA

-0.47

YoY

570.40%

Last updated:

Total Debt to EBITDA Ratio of STCube is 2024 -0.47 . Total Debt to EBITDA Ratio of STCube was 2023 -0.07 . It decreases by 570.40% lower compared to the previous year.

The STCube Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
-0.03 KRW
Jan 1, 2018
-1.09 KRW
Jan 1, 2019
-1.72 KRW
Jan 1, 2020
-0.44 KRW
Jan 1, 2021
-0.21 KRW
Jan 1, 2022
-0.11 KRW
Jan 1, 2023
-0.07 KRW
Jan 1, 2024
-0.47 KRW
The STCube Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.47+570.40%
-0.07-33.68%
-0.11-49.11%
-0.21-52.35%
-0.44-74.67%
-1.72+57.38%
-1.09+3,109.88%
-0.03-98.21%
-1.91—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Total Debt to EBITDA Ratio of STCube is -0.47 in 2024.

Total Debt to EBITDA Ratio of STCube changed from -0.07 to -0.47, representing a 570.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio STCube since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's STCube with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — STCube

All Key Metrics — STCube